Drug Profile
Research programme: neurological disorders therapies - AbbVie/Syntaxin
Alternative Names: SXN 113Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Health Protection Agency
- Developer Syntaxin
- Class Analgesics; Botulinum toxins; Recombinant proteins
- Mechanism of Action SNARE protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 23 Jul 2013 No development reported - Preclinical for Neurological disorders in United Kingdom (unspecified route)
- 23 Jul 2013 No development reported - Preclinical for Neurological disorders in USA (unspecified route)